Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab

Prognostic factor analysis has been conducted to determine whether the parameters of clinical data and biomarkers would predict differential progression-free survival (PFS) or overall survival (OS) from lapatinib-based therapy in patients with primary or acquired resistance to trastuzumab. Treatment...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Bian, Li, Wang, Tao, Zhang, Shao-hua, Zhang, Hui-qiang, Guo, Yun-fei, Du, Ge, Li, Wang, Wu, Shi-kai, Song, San-tai, Jiang, Ze-fei
פורמט: Artigo
שפה:Inglês
יצא לאור: Landes Bioscience 2014
נושאים:
Clinical Study
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3979813/
https://ncbi.nlm.nih.gov/pubmed/24424115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.27624
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים